ReviewJournal of clinical medicine2019
Sugar-Lowering Drugs for Type 2 Diabetes Mellitus and Metabolic Syndrome-Strategies for In Vivo Administration: Part-II.
Review in Journal of clinical medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 69 citations in OpenAlex.
- Research on the mechanism of cow milk protein dietary intervention in ameliorating systemic chronic inflammation in type 2 diabetes by disrupting the ROS-M1 macrophage axis.Frontiers in nutrition · 2026Article
- Article
- Deletion of CHOP in beta cell protects mice from cardiovascular complications in type 2 diabetes: evidence from a pre-clinical mouse model.Journal of molecular and cellular cardiology plus · 2025Article
- Novel insights into beta cell ER stress CHOP and its role in HFpEF development.Cardiovascular diabetology · 2025Article
- Article
- Exploring the Biological Effects of Anti-Diabetic Vanadium Compounds in the Liver, Heart and Brain.Diabetes, metabolic syndrome and obesity : targets and therapy · 2024Review
- Impact of Glycemic Control on Shoulder Proprioception in Type 2 Diabetes Mellitus: Mediating the Connection - Insights from a Cross-Sectional Analysis.Journal of multidisciplinary healthcare · 2024Article
- Diabetic retinopathy: a comprehensive update on in vivo, in vitro and ex vivo experimental models.BMC ophthalmology · 2023Review
- Clinical characteristics and acute complication of COVID-19 patients with diabetes: a multicenter, retrospective study in Southern China.Frontiers in endocrinology · 2023Article
- Article
- An Overview of Herbal-Based Antidiabetic Drug Delivery Systems: Focus on Lipid- and Inorganic-Based Nanoformulations.Pharmaceutics · 2022Review
- Simple, Sensitive, and Rapid Voltammetric Detection of Alloxan on Glassy Carbon Electrodes.ACS omega · 2022Article
- The Evolution of Pharmacological ActivitiesPharmaceuticals (Basel, Switzerland) · 2022Review
- Streptozotocin-Induced Diabetes in a Mouse Model (BALB/c) Is Not an Effective Model for Research on Transplantation Procedures in the Treatment of Type 1 Diabetes.Biomedicines · 2021Article
- Experimental animal models for diabetes and its related complications-a review.Laboratory animal research · 2021Review
- Plants and Diabetes: Description, Role, Comprehension and Exploitation.International journal of molecular sciences · 2021Article
- Sub-chronic microcystin-LR renal toxicity in rats fed a high fat/high cholesterol diet.Chemosphere · 2021Article
- Biomedical Potential of Plant-Based Selenium Nanoparticles: A Comprehensive Review on Therapeutic and Mechanistic Aspects.International journal of nanomedicine · 2021Review
- Biological efficacy of zinc oxide nanoparticles against diabetes: a preliminary study conducted in mice.Bioscience reports · 2020Article
- In Vitro Characterization, Modelling, and Antioxidant Properties of Polyphenon-60 from Green Tea in Eudragit S100-2 Chitosan Microspheres.Nutrients · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 8 institutions in 5 countries.
Funding
Abstract
Diabetes is a complex disease characterized by hyperglycemia, together with polyuria, polydipsia, and polyphagia. While Type 1 diabetes mellitus (T1DM) results from genetic, environmental, or immune dysfunction factors leading to pancreatic β-cell destruction depriving the organism from endogenous insulin, Type 2 diabetes mellitus (T2DM) is characterized by peripheral insulin resistance. Depending on the type of diabetes mellitus and drug mechanism to study, the animal model should be carefully selected among the wide variety of the currently available ones. This review discusses the most common animal models currently employed to study T1DM and T2DM. Moreover, an overview on the administration routes that could be used is also discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.